MYCN and neoplasm: More importantly, only tumors treated with DZNep exhibited MYCN (and EZH2) loss even though 50 mg/kg of GSK126 was as capable as 3 mg/kg of DZNep in diminishing H3K27me3 expression within tumor cells (Fig. 6d, compare the H3K27me3 immunochemistry images between GSK126 and DZNep treatment).